Skip to main content
Top
Published in: Pituitary 2/2008

01-06-2008

Drugs and prolactin

Author: Mark E. Molitch

Published in: Pituitary | Issue 2/2008

Login to get access

Abstract

Medications commonly cause hyperprolactinemia and their use must be differentiated from pathologic causes. The most common medications to cause hyperprolactinemia are the antipsychotic agents, although some of the newer atypical antipsychotics do not do so. Other medications causing hyperprolactinemia include antidepressants, antihypertensive agents, and drugs which increase bowel motility. Often, the medication-induced hyperprolactinemia is symptomatic, causing galactorrhea, menstrual disturbance, and erectile dysfunction. In the individual patient, it is important differentiate hyperprolactinemia due to a medication from a structural lesion in the hypothalamic–pituitary area. This can be done by stopping the medication temporarily to determine if the prolactin (PRL) levels return to normal, switching to another medication in the same class which does not cause hyperprolactinemia (in consultation with the patient’s physician and/or psychiatrist), or by performing an MRI or CT scan. If the hyperprolactinemia is symptomatic, management strategies include switching to an alternative medication which does not cause hyperprolactinemia, using estrogen/testosterone replacement, or cautiously adding a dopamine agonist.
Literature
2.
go back to reference Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 17:213–223PubMed Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 17:213–223PubMed
4.
go back to reference Maguire A (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56–62. MedlinePubMed Maguire A (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56–62. MedlinePubMed
7.
go back to reference Langer G, Sachar EJ, Halpern FS (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine. J Clin Endocrinol Metab 45:996–1002. MedlinePubMed Langer G, Sachar EJ, Halpern FS (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine. J Clin Endocrinol Metab 45:996–1002. MedlinePubMed
9.
go back to reference Meltzer HY, Fang VS (1976) Serum prolactin levels in schizophrenia—effect of antipsychotic drugs: a preliminary report. In: Sachar J (ed) Hormones, behavior, and psychopathology. Raven Press, New York, NY, pp 177–190 Meltzer HY, Fang VS (1976) Serum prolactin levels in schizophrenia—effect of antipsychotic drugs: a preliminary report. In: Sachar J (ed) Hormones, behavior, and psychopathology. Raven Press, New York, NY, pp 177–190
10.
go back to reference De Rivera JL, Lal S, Ettigi P et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282. MedlineCrossRef De Rivera JL, Lal S, Ettigi P et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282. MedlineCrossRef
15.
18.
go back to reference Kearns AE, Goff DC, Hayden DL et al (2000) Risperidone-associated hyperprolactinemia. Endocr Pract 6:425–429. MedlinePubMed Kearns AE, Goff DC, Hayden DL et al (2000) Risperidone-associated hyperprolactinemia. Endocr Pract 6:425–429. MedlinePubMed
20.
go back to reference Becker D, Liver O, Mester R et al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64:761–766. MedlinePubMed Becker D, Liver O, Mester R et al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64:761–766. MedlinePubMed
21.
go back to reference Findling RL, Kusumakar V, Daneman D et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362–1369. MedlinePubMedCrossRef Findling RL, Kusumakar V, Daneman D et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362–1369. MedlinePubMedCrossRef
22.
go back to reference Volavka J, Czobor P, Cooper TB et al (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57–61. MedlinePubMed Volavka J, Czobor P, Cooper TB et al (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57–61. MedlinePubMed
24.
go back to reference Pandurangi AK, Narasimhachari N, Blackard WG et al (1989) Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 50:379–381. MedlinePubMed Pandurangi AK, Narasimhachari N, Blackard WG et al (1989) Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 50:379–381. MedlinePubMed
25.
go back to reference Breier AF, Malhotra AK, Su T-P et al (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294–298. MedlinePubMed Breier AF, Malhotra AK, Su T-P et al (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294–298. MedlinePubMed
28.
go back to reference Kim K-S, Pae C-U, Hae J-H et al (2002) Effects of olanzapine on prolactin levels of female patients treated with schizophrenia treated with risperidone. J Clin Psychiatry 63:408–413. MedlinePubMed Kim K-S, Pae C-U, Hae J-H et al (2002) Effects of olanzapine on prolactin levels of female patients treated with schizophrenia treated with risperidone. J Clin Psychiatry 63:408–413. MedlinePubMed
29.
go back to reference Hamner MB, Arvanitis LA, Miller BG et al (1996) Plasma prolactin in schizophrenia subjects treated with SeroquelTM (ICI 204,636). Psychopharmacol Bull 32:107–110. MedlinePubMed Hamner MB, Arvanitis LA, Miller BG et al (1996) Plasma prolactin in schizophrenia subjects treated with SeroquelTM (ICI 204,636). Psychopharmacol Bull 32:107–110. MedlinePubMed
31.
go back to reference Goff DC, Posever T, Herz L et al (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296–304. Medline. doi:10.1097/00004714-199808000-00009 PubMedCrossRef Goff DC, Posever T, Herz L et al (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296–304. Medline. doi:10.​1097/​00004714-199808000-00009 PubMedCrossRef
32.
go back to reference Casey DE, Carson WH, Saha AR, Aripiprazole Study Group et al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399. Medline Casey DE, Carson WH, Saha AR, Aripiprazole Study Group et al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399. Medline
34.
go back to reference Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38. MedlinePubMed Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38. MedlinePubMed
35.
go back to reference Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607–1618. MedlinePubMed Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607–1618. MedlinePubMed
41.
go back to reference Ataya K, Abbasi A, Mercado A et al (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876–881. MedlinePubMed Ataya K, Abbasi A, Mercado A et al (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876–881. MedlinePubMed
43.
go back to reference Meltzer HY, Fang VS, Tricou BJ et al (1982) Effect of antidepressants on neuroendocrine axis in humans. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: clinical practice. Raven Press, New York, NY, pp 303–316 Meltzer HY, Fang VS, Tricou BJ et al (1982) Effect of antidepressants on neuroendocrine axis in humans. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: clinical practice. Raven Press, New York, NY, pp 303–316
44.
go back to reference Price LH, Charney DS, Delgado PL et al (1989) Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625–631. MedlinePubMed Price LH, Charney DS, Delgado PL et al (1989) Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625–631. MedlinePubMed
45.
go back to reference Jones RB, Luscombe DK, Groom GV (1977) Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J 53(Suppl 4):166–71PubMed Jones RB, Luscombe DK, Groom GV (1977) Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J 53(Suppl 4):166–71PubMed
46.
go back to reference Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11:851–856. MedlinePubMed Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11:851–856. MedlinePubMed
49.
go back to reference Cohen MA, Davies PH (1998) Drug therapy and hyperprolactinaemia. Adverse Drug React Bull 190:723–726CrossRef Cohen MA, Davies PH (1998) Drug therapy and hyperprolactinaemia. Adverse Drug React Bull 190:723–726CrossRef
50.
go back to reference Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147–152. MedlinePubMed Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147–152. MedlinePubMed
51.
go back to reference Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11:345–348. MedlinePubMedCrossRef Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11:345–348. MedlinePubMedCrossRef
53.
55.
go back to reference Shlik J, Aluoja A, Vasar V et al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340. MedlinePubMed Shlik J, Aluoja A, Vasar V et al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340. MedlinePubMed
56.
go back to reference Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 137:201–202. Medline. doi:10.1007/s002130050610 CrossRef Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 137:201–202. Medline. doi:10.​1007/​s002130050610 CrossRef
57.
go back to reference Šagud M, Pivac N, Mück-Šeler D et al (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45:139–143. Medline. doi:10.1159/000054954 PubMedCrossRef Šagud M, Pivac N, Mück-Šeler D et al (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45:139–143. Medline. doi:10.​1159/​000054954 PubMedCrossRef
60.
go back to reference Peterson MC (2001) Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76:215–216. MedlinePubMed Peterson MC (2001) Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76:215–216. MedlinePubMed
62.
go back to reference Walsh AE, Cowen PJ (1994) Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 14:268–273. MedlinePubMed Walsh AE, Cowen PJ (1994) Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 14:268–273. MedlinePubMed
63.
go back to reference Whiteman PD, Peck AW, Fowle AS et al (1983) Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 44:209–210. MedlinePubMed Whiteman PD, Peck AW, Fowle AS et al (1983) Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 44:209–210. MedlinePubMed
67.
go back to reference Batürk M, Karaaslan F, Eşel E et al (2001) Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:315–322. Medline. doi:10.1016/S0278-5846(00)00165-2 CrossRef Batürk M, Karaaslan F, Eşel E et al (2001) Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:315–322. Medline. doi:10.​1016/​S0278-5846(00)00165-2 CrossRef
68.
go back to reference Tolis G, Hickey J, Guyda H (1975) Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 41:797–800. MedlinePubMed Tolis G, Hickey J, Guyda H (1975) Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 41:797–800. MedlinePubMed
70.
go back to reference Chan V, Wang C, Yeung TT (1979) Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men. Clin Endocrinol (Oxf) 10:557–565. MedlineCrossRef Chan V, Wang C, Yeung TT (1979) Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men. Clin Endocrinol (Oxf) 10:557–565. MedlineCrossRef
73.
go back to reference Panerai AE, Petraglia F, Sacerdote P et al (1985) Mainly μ-opiate receptors are involved in luteinizing hormone and prolactin secretion. Endocrinology 117:1096–1099. MedlinePubMed Panerai AE, Petraglia F, Sacerdote P et al (1985) Mainly μ-opiate receptors are involved in luteinizing hormone and prolactin secretion. Endocrinology 117:1096–1099. MedlinePubMed
74.
go back to reference Pfeiffer A, Braun S, Mann K (1986) Anterior pituitary hormone responses to a k-opioid agonist in man. J Clin Endocrinol Metab 62:181–185. MedlinePubMed Pfeiffer A, Braun S, Mann K (1986) Anterior pituitary hormone responses to a k-opioid agonist in man. J Clin Endocrinol Metab 62:181–185. MedlinePubMed
75.
go back to reference Leadem CA, Yagenova SV (1987) Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45:109–117. MedlinePubMedCrossRef Leadem CA, Yagenova SV (1987) Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45:109–117. MedlinePubMedCrossRef
77.
go back to reference Van Loon GR, Ho D, Kim C (1980) ß-endorphin-induced decrease in hypothalamic dopamine turnover. Endocrinology 106:76–80. MedlinePubMed Van Loon GR, Ho D, Kim C (1980) ß-endorphin-induced decrease in hypothalamic dopamine turnover. Endocrinology 106:76–80. MedlinePubMed
80.
go back to reference Mendelson JH, Mello NK, Teoh SK et al (1989) Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256–1260. MedlinePubMed Mendelson JH, Mello NK, Teoh SK et al (1989) Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256–1260. MedlinePubMed
81.
go back to reference Maestri E, Camellini L, Rossi G et al (1985) Effects of five days verapamil administration on serum GH and PRL levels. Horm Metab Res 17:482. MedlinePubMedCrossRef Maestri E, Camellini L, Rossi G et al (1985) Effects of five days verapamil administration on serum GH and PRL levels. Horm Metab Res 17:482. MedlinePubMedCrossRef
83.
go back to reference Kelley SR, Kamal TJ, Molitch ME (1996) Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 270 (Endocrinol Metab 33):E96–E100 Kelley SR, Kamal TJ, Molitch ME (1996) Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 270 (Endocrinol Metab 33):E96–E100
84.
go back to reference Gluskin LE, Strasberg B, Shah JH (1981) Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med 95:66–67. MedlinePubMed Gluskin LE, Strasberg B, Shah JH (1981) Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med 95:66–67. MedlinePubMed
87.
go back to reference Steiner J, Cassar J, Mashiter K et al (1976) Effect of methyldopa on prolactin and growth hormone. BMJ 1:1186–1188. MedlinePubMed Steiner J, Cassar J, Mashiter K et al (1976) Effect of methyldopa on prolactin and growth hormone. BMJ 1:1186–1188. MedlinePubMed
89.
go back to reference Winer LM, Molteni A, Molitch ME (1990) Effect of angiotensin—converting enzyme inhibition on pituitary hormone response to insulin—induced hypoglycemia in humans. J Clin Endocrinol Metab 71:256–259. MedlinePubMed Winer LM, Molteni A, Molitch ME (1990) Effect of angiotensin—converting enzyme inhibition on pituitary hormone response to insulin—induced hypoglycemia in humans. J Clin Endocrinol Metab 71:256–259. MedlinePubMed
90.
go back to reference Barbieri C, Larovere MT, Mariotti G et al (1982) Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 16:615–619. MedlineCrossRef Barbieri C, Larovere MT, Mariotti G et al (1982) Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 16:615–619. MedlineCrossRef
91.
go back to reference Aono T, Shioji T, Kinugasa T et al (1978) Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab 47:675–680. MedlinePubMedCrossRef Aono T, Shioji T, Kinugasa T et al (1978) Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab 47:675–680. MedlinePubMedCrossRef
92.
go back to reference Tamagna EI, Lane WS, Hershman JM et al (1979) Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res 11:161–169. MedlinePubMedCrossRef Tamagna EI, Lane WS, Hershman JM et al (1979) Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res 11:161–169. MedlinePubMedCrossRef
93.
go back to reference Fujino T, Kato H, Yamashita S et al (1980) Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn 27:521–525PubMed Fujino T, Kato H, Yamashita S et al (1980) Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn 27:521–525PubMed
97.
go back to reference Majumdar SK, Thomson AD, Shaw GK (1978) Cimetidine and serum prolactin. BMJ 1:409–410. MedlinePubMed Majumdar SK, Thomson AD, Shaw GK (1978) Cimetidine and serum prolactin. BMJ 1:409–410. MedlinePubMed
98.
go back to reference Scarpignato C, Bertaccini G (1979) Cimetidine and endocrine secretions: a short review. Drugs Exp Clin Res 5:129–140 Scarpignato C, Bertaccini G (1979) Cimetidine and endocrine secretions: a short review. Drugs Exp Clin Res 5:129–140
105.
go back to reference Reyniak JV, Wenof M, Aubert JM et al (1980) Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 55:8–11. MedlinePubMed Reyniak JV, Wenof M, Aubert JM et al (1980) Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 55:8–11. MedlinePubMed
106.
go back to reference Luciano AA, Sherman BM, Chapler FK et al (1985) Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65:506. MedlinePubMed Luciano AA, Sherman BM, Chapler FK et al (1985) Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65:506. MedlinePubMed
108.
go back to reference Davis JRE, Selby C, Jeffcoate WJ (1984) Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427–434. MedlineCrossRef Davis JRE, Selby C, Jeffcoate WJ (1984) Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427–434. MedlineCrossRef
109.
go back to reference Hwang PLH, Ng CSA, Cheong ST (1986) Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 24:127–133. MedlineCrossRef Hwang PLH, Ng CSA, Cheong ST (1986) Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 24:127–133. MedlineCrossRef
110.
go back to reference Josimovich JB, Lavenhar MA, Devanesan MM et al (1987) Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 47:785–791. MedlinePubMed Josimovich JB, Lavenhar MA, Devanesan MM et al (1987) Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 47:785–791. MedlinePubMed
113.
go back to reference Perrone G, Falaschi P, Capri O et al (1994) Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 39:202–207. MedlinePubMed Perrone G, Falaschi P, Capri O et al (1994) Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 39:202–207. MedlinePubMed
114.
go back to reference Castel-Branco C, Martínez de Osaba MJ, Fortuny A et al (1995) Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison J Reprod Med 40:556–560. Medline Castel-Branco C, Martínez de Osaba MJ, Fortuny A et al (1995) Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison J Reprod Med 40:556–560. Medline
115.
go back to reference Foth D, Römer T (1997) Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 44:124–126. MedlinePubMed Foth D, Römer T (1997) Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 44:124–126. MedlinePubMed
118.
go back to reference Siegel YI, Korczak D, Lindner A (1991) Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 19:16–18. MedlinePubMed Siegel YI, Korczak D, Lindner A (1991) Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 19:16–18. MedlinePubMed
119.
go back to reference Kauschansky A, Nussinovitch M, Frydman M et al (1995) Hyperprolactinemia after treatment of long-acting gonadotropin-releasing analogue Decapetyl in girls with central precocious puberty. Fertil Steril 64:285–287. MedlinePubMed Kauschansky A, Nussinovitch M, Frydman M et al (1995) Hyperprolactinemia after treatment of long-acting gonadotropin-releasing analogue Decapetyl in girls with central precocious puberty. Fertil Steril 64:285–287. MedlinePubMed
121.
go back to reference Molitch ME, Reichlin S (1985) Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin basic and clinical correlates. Liviana Press, Padova, Italy, pp 709–719 Molitch ME, Reichlin S (1985) Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin basic and clinical correlates. Liviana Press, Padova, Italy, pp 709–719
125.
go back to reference Takahashi H, Higuchi H, Kamata M et al (2003) Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsyc Clin Neurosci 15:375–377 Takahashi H, Higuchi H, Kamata M et al (2003) Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsyc Clin Neurosci 15:375–377
128.
go back to reference Kinon BJ, Ahl J, Liu-Seifert H et al (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588. Medline. doi:10.1016/j.psyneuen.2005.12.006 PubMedCrossRef Kinon BJ, Ahl J, Liu-Seifert H et al (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588. Medline. doi:10.​1016/​j.​psyneuen.​2005.​12.​006 PubMedCrossRef
130.
go back to reference Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W (1975) Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry 126:285–288. MedlinePubMedCrossRef Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W (1975) Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry 126:285–288. MedlinePubMedCrossRef
131.
go back to reference Cohen JB, Brust J, DiSerio F, Singer J (1985) Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 13:173–179. MedlineCrossRef Cohen JB, Brust J, DiSerio F, Singer J (1985) Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 13:173–179. MedlineCrossRef
132.
go back to reference Smith J (1992) Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 37:737–740. MedlinePubMed Smith J (1992) Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 37:737–740. MedlinePubMed
133.
go back to reference Tollin SR (2000) Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23:765–770. MedlinePubMed Tollin SR (2000) Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23:765–770. MedlinePubMed
134.
go back to reference Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E (2004) Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187–190. MedlinePubMedCrossRef Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E (2004) Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187–190. MedlinePubMedCrossRef
136.
go back to reference Frye PE, Pariser SF, Kim MH et al (1982) Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 43:252–253. MedlinePubMed Frye PE, Pariser SF, Kim MH et al (1982) Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 43:252–253. MedlinePubMed
Metadata
Title
Drugs and prolactin
Author
Mark E. Molitch
Publication date
01-06-2008
Publisher
Springer US
Published in
Pituitary / Issue 2/2008
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0106-6

Other articles of this Issue 2/2008

Pituitary 2/2008 Go to the issue

OriginalPaper

Male hypogonadism

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine